PE20020784A1 - METHOD FOR IDENTIFYING TISSUE-SPECIFIC PROGESTERONE RECEPTOR BINDERS FOR ISOFORMS AND TISSUE SELECTIVE PROGESTERONE RECEPTOR BINDERS - Google Patents

METHOD FOR IDENTIFYING TISSUE-SPECIFIC PROGESTERONE RECEPTOR BINDERS FOR ISOFORMS AND TISSUE SELECTIVE PROGESTERONE RECEPTOR BINDERS

Info

Publication number
PE20020784A1
PE20020784A1 PE2001001311A PE2001001311A PE20020784A1 PE 20020784 A1 PE20020784 A1 PE 20020784A1 PE 2001001311 A PE2001001311 A PE 2001001311A PE 2001001311 A PE2001001311 A PE 2001001311A PE 20020784 A1 PE20020784 A1 PE 20020784A1
Authority
PE
Peru
Prior art keywords
cells
tissue
gene
plasmid
progesterone receptor
Prior art date
Application number
PE2001001311A
Other languages
Spanish (es)
Inventor
Ulrike Furhrmann
Michael Klotzbuecher
Christia Hegele-Hartung
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20020784A1 publication Critical patent/PE20020784A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Abstract

SE REFIERE A UN METODO PARA IDENTIFICAR LIGANDOS ESPECIFICOS DE LA ISOFORMA DEL RECEPTOR DE PROGESTERONA A O B (PR) QUE COMPRENDE: a)TRANSFECTAR EN FORMA ESTABLE UN GRUPO 1 DE CELULAS COMO CELULAS DEL NEUROBLASTOMA HUMANO CON UN PLASMIDO TAL COMO PROMOTOR DEL VIRUS DE TUMOR MAMARIO DEL RATON QUE EXPRESA LA ISOFORMA DEL RECEPTOR DE PR A; b)TRANSFECTAR EN FORMA ESTABLE UN GRUPO 2 DE CELULAS CON UN PLASMIDO QUE EXPRESA LA ISOFORMA DEL RECEPTOR DE PR B; c)TRANSFECTAR LOS GRUPOS 1 Y 2 DE CELULAS CON UN PLASMIDO QUE COMPRENDE UN GEN INFORMANTE TAL COMO EL GEN DE LUCIFERASA, CONECTADO CON UN PROMOTOR QUE RESPONDE A HORMONAS; d)PONER EN CONTACTO LOS GRUPOS 1 Y 2 DE CELULAS CON UN LIGANDO A EVALUAR; e)DETERMINAR LA EFICACIA DE LA TRANSCRIPCION O POTENCIA DEL GEN INFORMANTE EN LOS GRUPOS 1 Y 2 DE CELULAS; f)SELECCIONAR UN LIGANDO QUE TIENE UNA SELECTIVIDAD POR LA ISOFORMA DEL RECEPTOR DE PR A O B; LA DIFERENCIA EN LA EFICACIA DE LA TRANSCRIPCION ES MAYOR O IGUAL A 10% Y LA DIFERENCIA DE LA POTENCIA ES DE 10, QUE SE DETERMINA MIDIENDO LA ACTIVIDAD DE LA LUCIFERASA; LOS PLASMIDOS Y EL GEN COMPRENDEN UN ADEMAS UN GEN DE RESISTENCIA A ANTIBIOTICOS TAL COMO NEOMICINA O PUROMICINA. TAMBIEN SE REFIERE A UN METODO PARA IDENTIFICAR LIGANDOS DE RECEPTORES DE PR SELECTIVOS PARA TEJIDOS QUE COMPRENDE ADEMAS g)SOMETER EL LIGANDO SELECCIONADO A PRUEBAS IN VIVO EN UN PRIMER TEJIDO (DE MAMA) Y EN UN SEGUNDO TEJIDO (DE UTERO) BLANCO, h)SELECCIONAR EL LIGANDO QUE TIENE LA ACTIVIDAD DESEADAIT REFERS TO A METHOD FOR IDENTIFYING SPECIFIC LIGANDS OF THE PROGESTERONE AOB (PR) RECEPTOR ISOFORM, INCLUDING: a) TRANSFECTING IN A STABLE FORM A GROUP 1 OF CELLS AS HUMAN NEUROBLASTOMA CELLS WITH A PLASMID THUMAN PLASMID SUCH AS PRAMIRUS VAMUS OF THE MOUSE THAT EXPRESSES THE ISOFORM OF THE PR A RECEIVER; b) TRANSFECTING IN A STABLE FORM A GROUP 2 OF CELLS WITH A PLASMID THAT EXPRESSES THE ISOFORM OF THE PR B RECEIVER; c) TRANSFECTING GROUPS 1 AND 2 OF CELLS WITH A PLASMID THAT INCLUDES AN INFORMANT GENE SUCH AS THE LUCIFERASE GENE, CONNECTED WITH A PROMOTER THAT RESPONDS TO HORMONES; d) PUT IN CONTACT GROUPS 1 AND 2 OF CELLS WITH A LINKAGE TO BE EVALUATED; e) DETERMINE THE EFFECTIVENESS OF THE TRANSCRIPTION OR POWER OF THE REPORTING GENE IN GROUPS 1 AND 2 OF CELLS; f) SELECT A LIGAND THAT HAS A SELECTIVITY BY THE ISOFORM OF THE RECEIVER OF PR A OR B; THE DIFFERENCE IN THE EFFICIENCY OF THE TRANSCRIPTION IS GREATER OR EQUAL TO 10% AND THE DIFFERENCE IN THE POWER IS 10, WHICH IS DETERMINED BY MEASURING THE ACTIVITY OF THE LUCIFERASA; THE PLASMIDS AND THE GENE ALSO INCLUDE A GENE OF RESISTANCE TO ANTIBIOTICS SUCH AS NEOMYCIN OR PUROMYCIN. IT ALSO REFERS TO A METHOD FOR IDENTIFYING LIGANDS OF SELECTIVE PR RECEPTORS FOR TISSUES THAT ALSO INCLUDE g) SUBMITTING THE SELECTED LIGAND TO IN VIVO TESTING IN A FIRST TISSUE (OF BREAST) AND IN A SECOND TISSUE (OF UTERUS) SELECT THE LIGAND THAT HAS THE DESIRED ACTIVITY

PE2001001311A 2000-12-28 2001-12-28 METHOD FOR IDENTIFYING TISSUE-SPECIFIC PROGESTERONE RECEPTOR BINDERS FOR ISOFORMS AND TISSUE SELECTIVE PROGESTERONE RECEPTOR BINDERS PE20020784A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25831200P 2000-12-28 2000-12-28
US30587501P 2001-07-18 2001-07-18

Publications (1)

Publication Number Publication Date
PE20020784A1 true PE20020784A1 (en) 2002-10-03

Family

ID=26946565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001311A PE20020784A1 (en) 2000-12-28 2001-12-28 METHOD FOR IDENTIFYING TISSUE-SPECIFIC PROGESTERONE RECEPTOR BINDERS FOR ISOFORMS AND TISSUE SELECTIVE PROGESTERONE RECEPTOR BINDERS

Country Status (8)

Country Link
EP (1) EP1373888A2 (en)
JP (1) JP2004516841A (en)
AR (1) AR032050A1 (en)
AU (1) AU2002219218A1 (en)
NO (1) NO20032969L (en)
PE (1) PE20020784A1 (en)
UY (1) UY27107A1 (en)
WO (1) WO2002054064A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652768A (en) * 2002-03-11 2005-08-10 舍林股份公司 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replaceme
DE102007023614A1 (en) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula
DE102007049630A1 (en) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
DE102007032800A1 (en) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2070909A1 (en) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Non-steroidal progesterone receptor modulators
CN113801889B (en) * 2021-09-18 2023-04-07 中国农业科学院农业质量标准与检测技术研究所 Cell screening model, construction method and application thereof, saccharomycete, preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE4235220A1 (en) * 1992-10-13 1994-06-16 Schering Ag Gestagen effective 19,11ß-bridged 4-estrene
DE4337416A1 (en) * 1993-10-27 1995-05-04 Schering Ag 10,11beta-C¶2¶-bridged steroids
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE4413185A1 (en) * 1994-04-12 1995-10-19 Schering Ag 11beta, 19-bridged 13alpha alkyl steroids
DE19723722A1 (en) * 1997-05-30 1998-12-10 Schering Ag Nonsteroidal progestogens

Also Published As

Publication number Publication date
JP2004516841A (en) 2004-06-10
NO20032969D0 (en) 2003-06-27
WO2002054064A2 (en) 2002-07-11
EP1373888A2 (en) 2004-01-02
AR032050A1 (en) 2003-10-22
AU2002219218A1 (en) 2002-07-16
NO20032969L (en) 2003-08-28
UY27107A1 (en) 2002-03-22
WO2002054064A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
Li et al. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease
Lebeau et al. Staufen 2 regulates mGluR long-term depression and Map1b mRNA distribution in hippocampal neurons
Shan et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression
Qu et al. Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice
Park et al. TRP vanilloid 2 knock-out mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception
Indra et al. Temporally controlled targeted somatic mutagenesis in embryonic surface ectoderm and fetal epidermal keratinocytes unveils two distinct developmental functions of BRG1 in limb morphogenesis and skin barrier formation
Jazbutyte et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart
Bérard et al. Lung tumors in mice expressing an antisense RARβ2 transgene
Hakroush et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease
US10472631B2 (en) Materials and methods for modulation of tendon healing
Ghatak et al. Transforming growth factor β1 (TGFβ1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts
Mackintosh et al. The molecular pathogenesis of Ewing sarcoma
Johnson et al. Protease-activated receptor-2 (PAR-2)-mediated NF-κB activation suppresses inflammation-associated tumor suppressor microRNAs in oral squamous cell carcinoma
Lee et al. Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells
Schang et al. GnRH receptor gene expression in the developing rat hippocampus: transcriptional regulation and potential roles in neuronal plasticity
PE20020784A1 (en) METHOD FOR IDENTIFYING TISSUE-SPECIFIC PROGESTERONE RECEPTOR BINDERS FOR ISOFORMS AND TISSUE SELECTIVE PROGESTERONE RECEPTOR BINDERS
Hiramuki et al. Mest but not MiR-335 affects skeletal muscle growth and regeneration
Oskowitz et al. Drosha regulates hMSCs cell cycle progression through a miRNA independent mechanism
Danielson et al. Limited miR-17-92 overexpression drives hematologic malignancies
Kato et al. Dynamic stem cell selection safeguards the genomic integrity of the epidermis
Tanaka et al. Forced expression of Nanog in hematopoietic stem cells results in a γδT-cell disorder
Bertesi et al. Promoter methylation leads to decreased ZFP36 expression and deregulated NLRP3 inflammasome activation in psoriatic fibroblasts
Chen et al. The intragenic microRNA miR199A1 in the dynamin 2 gene contributes to the pathology of X-linked centronuclear myopathy
WO2016142703A1 (en) Biocompatible implants for use in tendon therapy
Zheng et al. A Cre-driver rat model for anatomical and functional analysis of glucagon (Gcg)-expressing cells in the brain and periphery

Legal Events

Date Code Title Description
FD Application declared void or lapsed